Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference

Rhea-AI Summary

Werewolf Therapeutics, Inc. (Nasdaq: HOWL), based in Cambridge, Massachusetts, will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021. CEO Daniel J. Hicklin, Ph.D. will provide a company overview available on-demand starting September 13 at 7:00 am EDT, archived for 90 days. Werewolf specializes in developing conditionally activated therapeutics to enhance the immune system's response to cancer, leveraging its innovative PREDATOR™ platform and its lead candidates, WTX-124 and WTX-330, for solid tumors.

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.

Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand beginning September 13 at 7:00 am EDT and will be archived for 90 days. A link to the webcast will be available at https://investors.werewolftx.com/news-and-events/events.

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

FAQ

What is Werewolf Therapeutics presenting at the H. C. Wainwright conference?

Werewolf Therapeutics will present an overview of the company at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021.

When can I watch the Werewolf Therapeutics presentation?

The presentation by Werewolf Therapeutics will be available on-demand starting September 13, 2021, at 7:00 am EDT.

How long will the Werewolf Therapeutics presentation be available?

The presentation will be archived and available for 90 days after the live event.

What are the main products of Werewolf Therapeutics?

Werewolf Therapeutics is focusing on WTX-124 and WTX-330, conditionally activated Interleukin-2 and Interleukin-12 molecules for solid tumors.

What does the PREDATOR™ platform do?

The PREDATOR™ platform is designed to create therapeutics that stimulate both adaptive and innate immune responses specifically in the tumor microenvironment.